ArriVent BioPharma, Inc.
AVBP
$20.11
$0.231.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 50.63% | 48.23% | 13.96% | 70.11% | 76.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.84% | 29.50% | 2.54% | 44.96% | 13.78% |
| Operating Income | -30.84% | -29.50% | -2.54% | -44.96% | -13.78% |
| Income Before Tax | -43.55% | -269.68% | 2.64% | -42.80% | -1.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -43.55% | -269.68% | 2.64% | -42.80% | -1.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.55% | -269.68% | 2.64% | -42.80% | -1.42% |
| EBIT | -30.84% | -29.50% | -2.54% | -44.96% | -13.78% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -37.39% | -173.14% | 92.16% | 88.91% | 93.95% |
| Normalized Basic EPS | -37.37% | -3.45% | 92.16% | 88.91% | 93.95% |
| EPS Diluted | -37.39% | -173.14% | 92.16% | 88.91% | 93.95% |
| Normalized Diluted EPS | -37.37% | -3.45% | 92.16% | 88.91% | 93.95% |
| Average Basic Shares Outstanding | 4.49% | 35.34% | 1,141.81% | 1,188.04% | 1,575.37% |
| Average Diluted Shares Outstanding | 4.49% | 35.34% | 1,141.81% | 1,188.04% | 1,575.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |